Having telehealth on the roster draws patients in

American Well, a provider of telehealth to more than 70 health systems, conducted its Telehealth Index: 2017 Consumer Survey, which showed 20 percent of patients would switch from a doctor who didn't offer telehealth visits to one who did.

The digital world isn’t just for younger generations. Healthcare providers embracing telehealth offer an easier way for patients to stay in contact. The survey was split into two parts, both focusing on gauging patients' interest in telehealth. One contained 2,100 adults aged 18 and older, with the second containing 2,007 adults.

Results included:

  • Overall, 65 percent of patients with a primary care physician (PCP) are interested in telehealth visits.
  • 74 percent of patients with children under 18 were more likely to be interested in telehealth visits.
  • 20 percent of consumers stated they would switch PCPs for one who offered telehealth visits.
  • 60 percent of those willing to try telehealth would see a PCP through telehealth to manage a chronic condition.
  • 79 percent of people caring for an ill or aging person said telehealth would be a helpful service.

“Consumers are clearly interested in more convenient access to healthcare—and increasingly, they are even willing to switch providers to get internet video service. Not only that, but consumers are willing to try telehealth for many needs—from chronic conditions to post-discharge follow up,” said Mary Modahl, the chief marketing officer at American Well.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.